Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies
Tags: biguanide, diabetes, Fortamet®, Glucophage®, glucose production inhibitor, Glumetza®, polycystic ovary syndrome
BASi Method Number SAP.705
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
